These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 35166158)

  • 1. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
    Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
    JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
    Calder AE; Rausch B; Liechti ME; Holze F; Hasler G
    J Psychopharmacol; 2024 Oct; 38(10):873-886. PubMed ID: 39302087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
    Rosenblat JD; Meshkat S; Doyle Z; Kaczmarek E; Brudner RM; Kratiuk K; Mansur RB; Schulz-Quach C; Sethi R; Abate A; Ali S; Bawks J; Blainey MG; Brietzke E; Cronin V; Danilewitz J; Dhawan S; Di Fonzo A; Di Fonzo M; Drzadzewski P; Dunlop W; Fiszter H; Gomes FA; Grewal S; Leon-Carlyle M; McCallum M; Mofidi N; Offman H; Riva-Cambrin J; Schmidt J; Smolkin M; Quinn JM; Zumrova A; Marlborough M; McIntyre RS
    Med; 2024 Mar; 5(3):190-200.e5. PubMed ID: 38359838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
    Poulin JM; Bigford GE; Lanctôt KL; Giacobbe P; Schaffer A; Sinyor M; Rabin JS; Masellis M; Singnurkar A; Pople CB; Lipsman N; Husain MI; Rosenblat JD; Cao X; MacIntosh BJ; Nestor SM
    Trials; 2024 Jul; 25(1):441. PubMed ID: 38956594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
    Raison CL; Sanacora G; Woolley J; Heinzerling K; Dunlop BW; Brown RT; Kakar R; Hassman M; Trivedi RP; Robison R; Gukasyan N; Nayak SM; Hu X; O'Donnell KC; Kelmendi B; Sloshower J; Penn AD; Bradley E; Kelly DF; Mletzko T; Nicholas CR; Hutson PR; Tarpley G; Utzinger M; Lenoch K; Warchol K; Gapasin T; Davis MC; Nelson-Douthit C; Wilson S; Brown C; Linton W; Ross S; Griffiths RR
    JAMA; 2023 Sep; 330(9):843-853. PubMed ID: 37651119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
    Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S
    J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
    Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.
    Agrawal M; Richards W; Beaussant Y; Shnayder S; Ameli R; Roddy K; Stevens N; Richards B; Schor N; Honstein H; Jenkins B; Bates M; Thambi P
    Cancer; 2024 Apr; 130(7):1137-1146. PubMed ID: 38105655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
    Griffiths R; Richards W; Johnson M; McCann U; Jesse R
    J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
    Olivier B; Olivier JDA
    Adv Exp Med Biol; 2024; 1456():49-66. PubMed ID: 39261423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of psilocybin therapy on personality structure.
    Erritzoe D; Roseman L; Nour MM; MacLean K; Kaelen M; Nutt DJ; Carhart-Harris RL
    Acta Psychiatr Scand; 2018 Nov; 138(5):368-378. PubMed ID: 29923178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.